GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » ROE % Adjusted to Book Value

Roche Holding AG (Roche Holding AG) ROE % Adjusted to Book Value : 4.67% (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Roche Holding AG ROE % Adjusted to Book Value?

Roche Holding AG's ROE % for the quarter that ended in Dec. 2023 was 31.84%. Roche Holding AG's PB Ratio for the quarter that ended in Dec. 2023 was 6.82. Roche Holding AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 4.67%.


Roche Holding AG ROE % Adjusted to Book Value Historical Data

The historical data trend for Roche Holding AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG ROE % Adjusted to Book Value Chart

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.38 5.93 3.60 5.65 6.10

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.13 6.50 3.58 6.43 4.67

Competitive Comparison of Roche Holding AG's ROE % Adjusted to Book Value

For the Drug Manufacturers - General subindustry, Roche Holding AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's ROE % Adjusted to Book Value falls into.



Roche Holding AG ROE % Adjusted to Book Value Calculation

Roche Holding AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=41.58% / 6.82
=6.10%

Roche Holding AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=31.84% / 6.82
=4.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (Roche Holding AG) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG (Roche Holding AG) Headlines

From GuruFocus